Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients With Post-COVID Conditions

NCT05592418 is registered in ClinicalTrials.gov with AIM ImmunoTech Inc. as lead sponsor.

NCT NCT05592418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05592418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients With Post-COVID Conditions
Lead sponsor
AIM ImmunoTech Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2023
Completion date
November 30, 2023
Enrollment
80 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

long covid, post covid-19 condition